Ben And Catherine Ivy Foundation

Organization Overview

Ben And Catherine Ivy Foundation is located in Scottsdale, AZ. The organization was established in 2007. According to its NTEE Classification (T20) the organization is classified as: Private Grantmaking Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations.

For the year ending 12/2019, Ben And Catherine Ivy Foundation generated $13.0m in total revenue. This organization has experienced exceptional growth, as over the past 2 years, it has increased revenue by an average of 22.0% each year . All expenses for the organization totaled $9.2m during the year ending 12/2019. You can explore the organizations financials more deeply in the financial statements section below.

Since 2019, Ben And Catherine Ivy Foundation has awarded 20 individual grants totaling $7,574,767. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.

Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Financial Statements

Statement of Revenue
Contributions, Gifts, Grants & Similar $11,047
Interest on Savings $1,146,779
Dividends & Interest $4,811,801
Net Rental Income$60,680
Net Gain on Sale of Assets $6,869,996
Capital Gain Net Income $6,869,996
Net ST Capital Gain $0
Income Modifications $0
Profit on Inventory Sales $0
Other Income $75,069
Total Revenue $12,975,372

Grants Awarded

Over the last fiscal year, Ben And Catherine Ivy Foundation has awarded $7,574,767 in support to 20 organizations.

Grant RecipientAmount

NEURO TRIALS LLC

PURPOSE: MULTIPLE AWARDS:1) DEVELOPMENT FO TRIPLE-DRUG COCKTAILS TO INDUCE GLIOBLASTOMA.2) UCSF PRECLINICAL CORE FOR DRUG DEVELOPMENT AT THE IVY BRAIN TUMOR CENTER.3)10 YEAR IBTC GRANT4) MATCHING FUNDS NATIONAL GBM DAY

$4,317,325

STANFORD UNIVERSITY

PURPOSE: YEAR 1 OF 3 YEAR AWARD: IMAGING TUMOR METABOLISM IN GBM PATIENTS TO HELP OPTIMIZE ANTI-TUMOR THERAPIES. THE ABILITY TO MONITOR PKM2, A KEY REGULATOR OF GBM METABOLISM, ALLOWS POTENIAL MONITORING ESSENTIAL TO EARLY THERAPY RESPONSE.

$1,024,920

CITY OF HOPE MEDICAL CENTER

Org PageRecipient Profile

Duarte, CA

PURPOSE: YEAR 2 OF 3 YEAR AWARD:ENGINEERING DE NOVO ANTITUMOR IMMUNITY USING PATIENT-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)-MODIFIED T CELLS. DEVELOPMENT OF A NEW CLASS OF CARS EXPLOITING THE BROAD AND SELECTIVE GBM BINDING PROPERTIES OF THE SCORPION TOXIN PEPTIDE CHLOROTOXIN (CTX) AND EVALUATE THE POTENTIAL OF A CTX-CAR TO LIMIT GBM ANTIGEN ESCAPE.

$957,527

Rochester, MN

PURPOSE: YEAR 4 OF 4 YEAR AWARD:AIM TO DRIVE CLINICAL DISCOVERY THROUGH OPTIMIZED MATHEMATICAL NEURO-ONCOLOGY RESPONSE METRICS BY CONNECTING PATIENT-SPECIFIC TREATMENT RESPONSE TO PATIENT SPECIFIC BENEFIT.

$500,000

SWEDISH MEDICAL CENTER

PURPOSE: FINAL PAYMENT THERAPEUTIC TARGETING OF MICROENVIRONMENTS WHICH WILL LEVERAGE THE IVY GLIOBLASTOMA ATLAS PROJECT TO IDENTIFY CANCER STEM CELL AND IMMUNE CELL COMPARTMENTS AND TO FUNCTIONALLY CHARACTERIZE AND TARGET THE CELLS IN THE CONTEXT OF THEIR MICROENVIRONMENTS.

$413,000

DAMON RUNYON CANCER RESEARCH FDN

PURPOSE: INVESTIGATION OF A BIOMARKER PHASE 2 STUDY TO EVALUATE TARGETED THERAPY HARBORING SPECIFIC GENETIC ALTERATIONS.

$200,000
View Grant Profile

Create an account to unlock the data you need.

or